Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2023-0140 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Katherine Appiah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cytel, Rotterdam, Netherlands. Hauptthemen laut MEDLINE: Advisory Committees, Biomedical Technology. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The drive to expedite patient access for diseases with high unmet treatment needs has come with an increasing use of single-arm trials (SATs), especially in oncology. However, the lack of control arms in such trials creates challenges to assess and demonstrate comparative efficacy. External control (EC) arms can be used to bridge this gap, with various types of sources available to obtain relevant data.
Objective
To examine the source of ECs in single-arm oncology health technology assessment (HTA) submissions to the National Institute for Health and Care Excellence (NICE) and the Pharmaceutical Benefits Advisory Committee (PBAC) and how this selection was justified by manufacturers and assessed by the respective HTA body.
Methods
Single-arm oncology HTA submission reports published by NICE (England) and PBAC (Australia) from January 2011 to August 2021 were reviewed, with data qualitatively synthesized to identify themes.
Results
Forty-eight oncology submissions using EC arms between 2011 and 2021 were identified, with most submissions encompassing blood and bone marrow cancers (52%). In HTA submissions to NICE and PBAC, the EC arm was typically constructed from a combination of data sources, with the company's justification in data source selection infrequently provided (PBAC [2 out of 19]; NICE [6 out of 29]), although this lack of justification was not heavily criticized by either HTA body.
Conclusion
Although HTA bodies such as NICE and PBAC encourage that EC source justification should be provided in submissions, this review found that this is not typically implemented in practice. Guidance is needed to establish best practices as to how EC selection should be documented in HTA submissions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cytel, Rotterdam, Netherlands.
- Cytel, London, UK.
- Takeda Pharmaceuticals America, Inc., Lexington, MA, USA.
Zitieren
APA
Appiah, K., Rizzo, M., Sarri, G., & Hernandez, L. (2024). Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0140
Vancouver
Appiah K, Rizzo M, Sarri G, Hernandez L. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0140
BibTeX
@article{Appiah2024,
author = {Appiah, Katherine and Rizzo, Maria and Sarri, Grammati and Hernandez, Luis},
title = {Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2023-0140}
}
EUVIMED